Document is current
Any future updates will be listed below
-
Authors
Spender, Lindsay C.
Watt, Dale M.
Baxter, Mark A. https://orcid.org/0000-0002-5773-8650
Shuttleworth, Morven K.
Walker, Kateah
Savage, Alice R.
Clements, Hollie A.
Kapelyukh, Yury
Bray, Susan E.
King, Sharon I.
Wolf, C. Roland
Inman, Gareth J. https://orcid.org/0000-0002-6264-4253
Walsh, Shaun V.
Blyth, Karen https://orcid.org/0000-0002-9304-439X
Petty, Russell D. https://orcid.org/0000-0003-2055-4572
-
Funding
Funding for this research was provided by:
Chief Scientist Office (TCS/19/18)
Cancer Research UK (A29799)
- License Information
-
More Information
Article History
Received: 29 October 2024
Revised: 10 May 2025
Accepted: 16 June 2025
First Online: 4 July 2025
Competing interests
: RDP is the subject editor for Clinical Studies at the British Journal of Cancer. RDP also declares Consulting or Advisory Role for Amgen, AstraZeneca, BMS, Servier, Astellas; Speaker fees received from BMS, Servicer; Travel Grant received from BMS, MSD; Institutional Research grants received from Amgen, Basilea, AstraZeneca, BMS, Five Prime Therapeutics, Platinum Therapeutics, Roche, MSD, Moderna, Astellas. MAB declares Consultancy for Servier; Speaker fees from BMS, AstraZeneca, MSD, Ipsen, Servier; Education/travel grant received from Ipsen, Servier. LCS, DHW, MKS, KW, ARS, HAC, YK, CRW, GJI, KB, SW, SB, and SK have no conflicts of interest to declare.
: Biospecimen collection was an optional part of the G02 trial design from the outset and was included in the trial ethical approval (REC Number 13/YH/0229). These samples were collected by the NHS Grampian Biorepository (16/NS/0055). The samples were also registered with the NHS Tayside Biorepository (REC approval 17/ES/0130). All methods were performed in accordance with the relevant guidelines and regulations.
